Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVR™, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of AVR.AX is 13 and suggests 4.34% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d